Chiesi Farmaceutici to acquire biopharma company Amryt Pharma for $1.5bn
Chiesi Farmaceutici, an Italian biopharmaceuticals and healthcare group, has agreed to acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in an all-cash transaction valued at around ... Read More
TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients
TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More